{"url_path":"/sec/rckt/8-k/2026-06-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-024997-index.html","accession_number":"0001140361-26-024997","cik":"0001281895","ticker":"RCKT","issuer_name":"ROCKET PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1281895/0001140361-26-024997-index.html","primary_entity_key":"0001281895","primary_entity_name":"ROCKET PHARMACEUTICALS, INC."},"word_count":81,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d)\n\nExhibits.\n\n[99.1](ef20076119_ex99-1.htm)\n\nPress Release of Rocket Pharmaceuticals, Inc. dated June 12, 2026.\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on\nits behalf by the undersigned hereunto duly authorized.\n\n \n\nRocket Pharmaceuticals, Inc.\n\n \n\n \n\n \n\nDate: June 12, 2026\n\nBy:\n\n/s/ Martin Wilson\n\n \n\n \n\nMartin Wilson\n\n \n\n \n\nGeneral Counsel and Chief Corporate Officer"}